

ASX RELEASE 5 September 2013

#### **Cleansing Notice**

We refer to the issue of a convertible security by Novogen Limited (**Novogen**) (**ASX: NRT**) on 5 July 2013. Pursuant to a notice of conversion of a portion of the convertible security representing in aggregate \$75,000, Novogen issued 506,757 ordinary shares to Merrill Lynch (Australia) Nominees Pty Limited ACN 003 925 031 FBO Hudson Bay Master Fund Limited on 5 September 2013 (**Shares**).

For the purposes of section 708A(5)(e)(i) of the Corporations Act 2001 (Cth) (**Corporations Act**) Novogen gives notice that:

- 1. Novogen issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
- 2. as at the date of this notice, Novogen has complied with:
  - (a) the provisions of Chapter 2M of the Corporations Act as they apply to Novogen; and
  - (b) section 674 of the Corporations Act; and
- 3. as at the date of this notice, there is no information that is "excluded information" (as defined in subsections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by Novogen.

Yours faithfully

Andrew Bursill

Company Secretary

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.		
	17.5	
<b>.</b> .		
	e of entity	
Nov	ogen Limited ("Novogen")	
ABN		
37 <sup>(</sup>	063 259 754	
We	(the entity) give ASX the following in	formation.
n	4.4 4.11 •	
	rt 1 - All issues	
You i	nust complete the relevant sections (attach sho	eets if there is not enough space).
1	*Class of *securities issued or to be	Ordinary fully paid share (Share)
	issued	
2	Number of *securities issued or to be	506,757 fully-paid Shares
_	issued (if known) or maximum	Society paid Charoc
	number which may be issued	
3	Principal terms of the *securities (eg,	Fully-paid ordinary voting shares
	if options, exercise price and expiry	Ranks pari passu with all existing Shares
	date; if partly paid *securities, the	
	amount outstanding and due dates for	
	amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for	

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	All of the Shares referred to in Item 2 will rank pari passu with all existing Ordinary Shares.
	If the additional securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do	
	not rank equally, other than in relation to the next dividend, distribution or interest payment	
_	Issue price or consideration	Issue price per Share: \$0.148
5	issue price of consideration	133de price per chare. \$6.146
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The Shares referred to in Item 2 are issued pursuant to a conversion notice received under the Convertible Securities Agreement announced to the market on 4 July 2013.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the +securities the	No
	subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A

Appendix 3B Page 2 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

6c	Number of +securities issued without security holder approval under rule 7.1	506,757 fully-paid Shares
6d	Number of +securities issued with security holder approval under rule 7.1A	N/A
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of +securities issued under an exception in rule 7.2	N/A
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A
c1	7.0	TALIA .
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
		[au/a
61	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A

<sup>+</sup> See chapter 19 for defined terms.

7	+Issue dates	5 September 2013	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of		
	Appendix 3B.		
		N	+Cl
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in clause 2 if applicable)	Number 143,691,221	+Class Ordinary Shares
		<b>X</b> 1	Lal.
9	Number and +class of all +securities not quoted on ASX (including the securities in clause	6,007,216	*Class Unlisted options with various exercise dates and prices.
	2 if applicable)		Unlisted convertible note with a face value of \$415,000
		, ,	Unlisted convertible notes, with aggregate face values of \$1,500,000
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part	2 - Bonus issue or pro	rata issue	
11	Is security holder approval required?		
12	Is the issue renounceable or non-		
14	renounceable?		
13	Ratio in which the *securities will be offered		

Appendix 3B Page 4 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?	
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>†</sup> Despatch date	
	et 3 - Quotation of securities eed only complete this section if you are applying for quotation of securities	
34	Type of securities (tick one)	
(a)	Securities described in Part 1	
(b)	All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	

Appendix 3B Page 6 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to locum	indicate you are providing the information or nts	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36	If the *securities are *equity securities, a distribution schedule of the addition *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 100,000  10,001 - 100,000  100,001 and over	
37	A copy of any trust deed for the additional *securities	
Enti	ies that have ticked box 34(b)	
38	Number of securities for which +quotation is sought	
39	Class of *securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	

<sup>+</sup> See chapter 19 for defined terms.

41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)		

Appendix 3B Page 8 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Company secretary)	Date: 5 September 2013
Print name:	Andrew Bursill	

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<b>Insert</b> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	103,805,676	
Add the following:		
<ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	34,470,357	
Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval	34,470,337	
Number of partly paid +ordinary securities that became fully paid in that 12 month period		
Note:		
Include only ordinary securities here – other classes of equity securities cannot be added		
• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed		
It may be useful to set out issues of securities on different dates as separate line items		
<b>Subtract</b> the number of fully paid +ordinary securities cancelled during that 12 month period	-	
"A"	138,276,033	

Appendix 3B Page 10 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
<b>Multiply</b> "A" by 0.15	20,741,404	
Step 3: Calculate "C", the amount of has already been used	placement capacity under rule 7.1 that	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:		
Under an exception in rule 7.2	9,415,188	
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
Note:		
This applies to equity securities, unless specifically excluded – not just ordinary securities		
Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed		
It may be useful to set out issues of securities on different dates as separate line items		
"C"	9,415,188	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	20,741,404	
Note: number must be same as shown in Step 2		
Subtract "C"	9,415,188	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	11,326,216	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	N/A	
<i>Multiply</i> "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of phas already been used	placement capacity under rule 7.1A that	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
Notes:		
• This applies to equity securities – not just ordinary securities		
• Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed		
• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained		
• It may be useful to set out issues of securities on different dates as separate line items		
"E"	N/A	

Appendix 3B Page 12 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	N/A
Note: number must be same as shown in Step 2	
Subtract "E"	N/A
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.